Summary
This technical report discusses the application of precision medicine in cancer treatment, focusing on the role of next-generation sequencing (NGS) technologies. It outlines how genome sequencing enables the identification of genetic changes in individual patients, allowing for the development of targeted treatment programs that enhance efficacy and minimize drug toxicity. The report describes the procedures followed at the Institute of Pathology and Neuropathology at Essen University Hospital, emphasizing their reliance on NGS for molecular analysis and diagnostics. The workflow for processing surgical specimens is detailed, including the use of various methods such as immunohistochemistry and fluorescence in situ hybridization. The report highlights the implementation of the Freedom EVO system, which has streamlined sample processing and reduced turnaround times for results. The collaboration with Tecan specialists is noted as a key factor in optimizing workflows and enhancing diagnostic capabilities, ultimately improving patient outcomes through faster and more accurate diagnoses.
